summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight
Pay in 4 interest-free payments of $5.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight](https://www.thelancet.com/cms/10.1016/S0140-6736(26)00656-2/asset/35b48abc-e313-46be-9a87-b6727032b3d4/main.assets/gr1_lrg.jpg)
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/styles/large_teaser/public/2025-02/e9c84c10-d166-4f6d-8f89-af229288169f.png?itok=cuyZfHY1)
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight](https://pandameds.com/wp-content/uploads/2026/02/Tirzepatide-vs-Semaglutide.webp)
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight](https://ars.els-cdn.com/content/image/1-s2.0-S0002870323002806-gr1.jpg)
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight](https://cdn.sanity.io/images/0vv8moc6/drugtopics/2c94dc74c6b22d9058bc5151cb6c572396d29216-3926x2944.jpg)

























